©2022 Stanford Medicine
This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.
Recruiting
Trial ID: NCT03818256
Purpose
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and
efficacy of miricorilant in obese adult with schizophrenia treated with antipsychotic
medications.
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)
Stanford Investigator(s)
Jacob S. Ballon
Clinical Professor, Psychiatry and Behavioral Sciences
Eligibility
Inclusion Criteria:
- Have a diagnosis of schizophrenia or bipolar disorder
- Are currently taking oral or injectable atypical antipsychotic medication (except
clozapine) and must have documented weight gain while on these medications
- Must be on a stable dose of medication for 1 month prior to screening
- Are able to successfully complete placebo tablet swallow test
- Have a BMI ≥30 kg/m2
Exclusion Criteria:
- Have a history of a medical condition affecting body weight (e.g., poorly controlled
hyper- or hypothyroidism; eating disorder such as anorexia, bulimia, or binge eating;
or polycystic ovary syndrome).
- Have poorly controlled diabetes mellitus
- Have poorly controlled hypertension
- Have a history of hypotension
- Have a history of orthostatic hypotension
Intervention(s):
drug: Miricorilant
drug: Miricorilant
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305